STIMULATION OF LABOR IN CASES OF PREMATURE RUPTURE OF THE MEMBRANES AT OR NEAR TERM

IF 3.5 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Acta Obstetricia et Gynecologica Scandinavica Pub Date : 2024-09-12 DOI:10.1111/j.1600-0412.1981.tb00039.x

Aksel P. Lange, Niels J. Secher, Folmer Hassing Nielsen, Gunnar Thomsen Pedersen

{"title":"STIMULATION OF LABOR IN CASES OF PREMATURE RUPTURE OF THE MEMBRANES AT OR NEAR TERM","authors":"Aksel P. Lange, Niels J. Secher, Folmer Hassing Nielsen, Gunnar Thomsen Pedersen","doi":"10.1111/j.1600-0412.1981.tb00039.x","DOIUrl":null,"url":null,"abstract":"Prostaglandin E2‐tablets were compared to in‐ravenous oxytocin for the stimulation of labor in 201 patients at or near term, with premature spontaneous rupture of the membranes without labor activity for 6 hours after the escape of fluid. The patients were randomly allocated; 99 were treated with PGE2‐tablets (0.5–1.5 mg/hour) and 102 with intravenous oxytocin (7.5–45 mIU/min).The treatment was ineffective in the PGE2 group in 3 cases; these were treated successfully with intravenous oxytocin. In the oxytocin group, 3 patients were delivered by cesarean section for reasons not associated with the drug. A significant difference was found in the stimulation‐delivery time, in favor of intravenous oxytocin.Although PGE2 tablets are a safe and convenient alternative to intravenous oxytocin, the investigation showed that intravenous oxytocin is preferable in cases of premature rupture of the membranes with more than 6 hours without labor activity.","PeriodicalId":6990,"journal":{"name":"Acta Obstetricia et Gynecologica Scandinavica","volume":"45 1","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Obstetricia et Gynecologica Scandinavica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/j.1600-0412.1981.tb00039.x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Prostaglandin E2‐tablets were compared to in‐ravenous oxytocin for the stimulation of labor in 201 patients at or near term, with premature spontaneous rupture of the membranes without labor activity for 6 hours after the escape of fluid. The patients were randomly allocated; 99 were treated with PGE2‐tablets (0.5–1.5 mg/hour) and 102 with intravenous oxytocin (7.5–45 mIU/min).The treatment was ineffective in the PGE2 group in 3 cases; these were treated successfully with intravenous oxytocin. In the oxytocin group, 3 patients were delivered by cesarean section for reasons not associated with the drug. A significant difference was found in the stimulation‐delivery time, in favor of intravenous oxytocin.Although PGE2 tablets are a safe and convenient alternative to intravenous oxytocin, the investigation showed that intravenous oxytocin is preferable in cases of premature rupture of the membranes with more than 6 hours without labor activity.

查看原文本刊更多论文

在胎膜早破或临近分娩时催产

对 201 名胎膜早破或临近分娩的患者进行了前列腺素 E2 药片与静脉催产素催产的比较，这些患者在流出液体后 6 小时内没有分娩活动。这些患者被随机分配，99 人接受 PGE2 片剂（0.5-1.5 毫克/小时）治疗，102 人接受静脉催产素（7.5-45 毫IU/分钟）治疗。在催产素组中，有 3 例患者因与药物无关的原因而剖宫产。虽然 PGE2 片剂是静脉催产素的安全、方便的替代品，但调查显示，在超过 6 小时没有分娩活动的胎膜早破病例中，静脉催产素更为可取。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Obstetricia et Gynecologica Scandinavica 医学-妇产科学

CiteScore

8.00

自引率

4.70%

发文量

180

审稿时长

3-6 weeks

期刊介绍： Published monthly, Acta Obstetricia et Gynecologica Scandinavica is an international journal dedicated to providing the very latest information on the results of both clinical, basic and translational research work related to all aspects of women’s health from around the globe. The journal regularly publishes commentaries, reviews, and original articles on a wide variety of topics including: gynecology, pregnancy, birth, female urology, gynecologic oncology, fertility and reproductive biology.